{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-25-027321","form_type":"8-K","ticker":"ANIX","cik":"0000715446","company_name":"Anixa Biosciences Inc","filed_at":"2025-12-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:41.975235+00:00","generated_at":"2026-05-16T13:25:39.382392+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Anixa reports final Phase 1 breast cancer vaccine data: 74% immune response, safe, advancing to Phase 2","bullets":["Vaccine met all primary endpoints; 74% of participants showed protocol-defined aLA-specific T cell responses.","Well tolerated at max tolerated dose; main adverse event was injection-site irritation; no flu-like symptoms.","Combination with Keytruda generated T cell responses without major additional side effects.","Enrolled 35 participants across three cohorts: early-stage TNBC, preventive mastectomy, adjuvant Keytruda.","Planning Phase 2 neoadjuvant combination study with Keytruda in newly diagnosed breast cancer patients."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-25-027321","json":"https://secwatch.observer/filing/0001493152-25-027321.json","markdown":"https://secwatch.observer/filing/0001493152-25-027321.md","text":"https://secwatch.observer/filing/0001493152-25-027321.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/715446/000149315225027321/0001493152-25-027321-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/715446/000149315225027321/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T13:25:39.382392+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}